Status:
COMPLETED
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
Lead Sponsor:
Abbott
Conditions:
Arthritis
Psoriatic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug T...
Eligibility Criteria
Inclusion
- Moderate to severe PsA
- Inadequate response to DMARD therapy
- Corticosteroid stable dose \<=10 mg QD
- DMARDs must have been taken for 3 months and stable dose for 4 weeks
- MTX maximum dose = \<=30 mg/week
- Active chronic plaque PS or documented history of chronic plaque PS
Exclusion
- No other active skin disease
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00646178
Start Date
June 1 2003
Last Update
March 28 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.